Berberine and Apixaban Interaction

Mechanism and Clinical Significance

• Apixaban is primarily metabolized via CYP3A4 and is also a substrate of P-gp/BCRP transporters, and when CYP3A4 is inhibited, apixaban plasma concentrations increase, leading to elevated bleeding risk, as recommended by the American Heart Association 1, 2
• Strong CYP3A4 inhibitors increase apixaban maximum concentration (Cmax) and area under the curve (AUC), significantly raising bleeding risk, according to the American College of Cardiology 2

Recommended Management Approach

• The European Society of Cardiology recommends avoiding apixaban with strong CYP3A4 and P-gp inhibitors, or reducing apixaban dose by 50% if combination is unavoidable, and considering alternative anticoagulants like edoxaban or low molecular weight heparin 2, 3, 4
• Edoxaban is minimally metabolized by CYP3A4 and represents the safest DOAC option with CYP3A4 inhibitors, as suggested by the European Respiratory Society 2, 3, 4

High-Risk Populations

• Elderly patients (>75 years), those with renal impairment (CrCl 30-50 mL/min), and patients weighing <50 kg face compounded bleeding risk when taking apixaban with berberine, according to the National Comprehensive Cancer Network 1, 6
• Apixaban clearance is already reduced in elderly patients and those with renal dysfunction, and adding a CYP3A4 inhibitor like berberine creates multiplicative risk, as warned by the American Geriatrics Society 1, 2

Monitoring Requirements

• Patients taking apixaban with berberine should be monitored closely for bleeding signs throughout berberine therapy and for 3-5 days after discontinuation, as recommended by the European Society of Cardiology 5, 2
• Renal function should be assessed before initiating combination and monitored for deterioration, according to the National Kidney Foundation 1